Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTGS2 | P35354 | 8/20 | 0.69 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.62 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.62 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.62 |
| ▸ | PTGS1 | P23219 | 3/20 | 0.60 |
| ▸ | CA12 | O43570 | 3/20 | 0.56 |
| ▸ | CA1 | P00915 | 3/20 | 0.56 |
| ▸ | CA2 | P00918 | 3/20 | 0.56 |
| ▸ | CA3 | P07451 | 3/20 | 0.56 |
| ▸ | CA4 | P22748 | 3/20 | 0.56 |
| ▸ | CA6 | P23280 | 3/20 | 0.56 |
| ▸ | CA5A | P35218 | 3/20 | 0.56 |
| ▸ | CA7 | P43166 | 3/20 | 0.56 |
| ▸ | CA9 | Q16790 | 3/20 | 0.56 |
| ▸ | CA13 | Q8N1Q1 | 3/20 | 0.56 |
| ▸ | CA14 | Q9ULX7 | 3/20 | 0.56 |
| ▸ | CA5B | Q9Y2D0 | 3/20 | 0.56 |
| ▸ | ENPP2 | Q13822 | 1/20 | 0.56 |
| ▸ | MAOB | P27338 | 1/20 | 0.56 |
| ▸ | AKR1C3 | P42330 | 2/20 | 0.53 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5052857 | 0.93 | PTGS2 (0.74) | PTGS2ALDH1A1CYP3A4MAPK1PTGS1 | |
| SCHEMBL2877698 | 0.87 | GSK3B (0.59) | PTGS2ALDH1A1CYP3A4MAPK1PTGS1 | |
| SCHEMBL7363201 | 0.87 | PTGS2 (0.56) | PTGS2ALDH1A1CYP3A4MAPK1PTGS1 | |
| SCHEMBL7679172 | 0.87 | PTGS2 (0.56) | PTGS2ALDH1A1CYP3A4MAPK1PTGS1 | |
| SCHEMBL2376239 | 0.85 | ENPP2 (0.72) | PTGS2ENPP2 | |
| SCHEMBL7814053 | 0.85 | MAOB (0.63) | PTGS2MAPK1MAOBAKR1C3AKR1C2 | |
| SCHEMBL12204147 | 0.85 | PTGS2 (0.55) | PTGS2ALDH1A1CYP3A4MAPK1PTGS1 | |
| SCHEMBL1528784 | 0.83 | PTGS2 (0.53) | PTGS2ALDH1A1CYP3A4MAPK1PTGS1 | |
| SCHEMBL6725659 | 0.83 | PTGS2 (1.00) | PTGS2PTGS1 | |
| SCHEMBL8974296 | 0.80 | PTGS2 (0.60) | PTGS2PTGS1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 745 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-118763273-A | Sulfonyl deep eutectic polymer electrolyte and preparation and application thereof | 青岛赛锂达储能产业技术研究院有限公司 | 2024-10-11 | — | — | CN | claimed |
| US-10806829-B2 | Antimicrobial medical devices | BECTON, DICKINSON AND COMPANY (US) | 2020-10-20 | — | — | US | claimed |
| CN-106866507-B | A kind of synthetic method for tieing up not Buddhist nun | 武汉博诚恒瑞医药科技有限公司 | 2019-08-02 | — | — | CN | claimed |
| CN-106892863-B | The preparation method of vismodegib and its intermediate | 山东大学 | 2019-06-11 | — | — | CN | claimed |
| WO-2019036650-A1 | ANTIMICROBIAL MEDICAL DEVICES | BECTON, DICKINSON AND COMPANY (US) | 2019-02-21 | — | — | WO | claimed |
| US-20190054213-A1 | Antimicrobial Medical Devices | BECTON, DICKINSON AND COMPANY | 2019-02-21 | — | — | US | claimed |
| CN-105017101-B | Synthesizing method of 2-chloro-4-(methylsulfonyl)benzoic acid | 浙江大学 | 2017-03-22 | — | — | CN | claimed |
| US-20100016336-A1 | HUMAN PROTEIN TYROSINE PHOSPHATASE INHIBITORS AND METHODS OF USE | EyePoint Pharmaceuticals, Inc. | 2010-01-21 | — | — | US | claimed |
| US-7622593-B2 | 4-{2-[2-(tert-Butoxycarbonyl)-3-phenylpropanamido]-2-(4-ethylthiazol-2-yl)ethyl}phenylsulfamic acid; anticarcinogenic, antitumor, antidiabrtic agent; angiogenesis inhibitor; sarcoid, syphilis, Paget's disease, vein occlusion, artery occlusion, carotid obstructive disease, chronic uveitis/vitritis | THE PROCTER & GAMBLE COMPANY (US) | 2009-11-24 | — | — | US | claimed |
| EP-2041102-A2 | HUMAN PROTEIN TYROSINE PHOSPHATASE INHIBITORS AND METHODS OF USE | The Procter & Gamble Company (US) | 2009-04-01 | — | — | EP | claimed |
| US-20060074113-A1 | Thiadiazoline derivative | KYOWA KIRIN CO., LTD. (JP) | 2006-04-06 | — | — | US | claimed |
| EP-1507776-A1 | 2-OXO-1,3,4-TRIHYDROQUINAZOLINYL DERIVATIVES FOR THE TREATMENT OF CELL PROLIFERATION-RELATED DISORDERS | Amgen Inc. (US) | 2005-02-23 | — | — | EP | claimed |
| EP-0929519-B1 | BETA-SULFONYL HYDROXAMIC ACIDS AS MATRIX METALLOPROTEINASES INHIBITORS | UPJOHN CO (US) | 2005-02-23 | — | — | EP | claimed |
| EP-1454903-A1 | THIADIAZOLINE DERIVATIVE | KYOWA HAKKO KOGYO CO., LTD. (JP) | 2004-09-08 | — | — | EP | claimed |
| US-20030229068-A1 | 2-oxo-1,3,4-trihydroquinazolinyl derivatives and methods of use | AMGEN INC. | 2003-12-11 | — | — | US | claimed |
| WO-2003101985-A1 | 2-OXO-1,3,4-TRIHYDROQUINAZOLINYL DERIVATIVES FOR THE TREATMENT OF CELL PROLIFERATION-RELATED DISORDERS | AMGEN INC. (US) | 2003-12-11 | — | — | WO | claimed |
| US-6235928-B1 | ENZYME INHIBITOR MATRIX METALLOPROTEINASE FAMILY, INCLUDING COLLAGENASE, STROMELYSIN, AND GELATINASE, THE COMPOUNDS OR PHARMACEUTICAL COMPOSITIONS | PHARMACIA & UPJOHN COMPANY | 2001-05-22 | — | — | US | claimed |
| EP-0929519-A1 | $g(b)-SULFONYL HYDROXAMIC ACIDS AS MATRIX METALLOPROTEINASES INHIBITORS | PHARMACIA & UPJOHN COMPANY (US) | 1999-07-21 | — | — | EP | claimed |
| US-5847153-A | β-sulfonyl hydroxamic acids | PHARMACIA & UPJOHN COMPANY (US) | 1998-12-08 | — | — | US | claimed |
| WO-1998013340-A1 | β-SULFONYL HYDROXAMIC ACIDS AS MATRIX METALLOPROTEINASES INHIBITORS | PHARMACIA & UPJOHN COMPANY (US) | 1998-04-02 | — | — | WO | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060074113-A1 | Thiadiazoline derivative | BRWD1, RB1, ARG2 | PTGS2 2406/4885ALDH1A1 343/4885CYP3A4 2717/4885 |
| US-20100016336-A1 | HUMAN PROTEIN TYROSINE PHOSPHATASE INHIBITORS AND METHODS OF USE | PTPRCAP, PTPRC, PPP5C | PTGS2 2991/4885ALDH1A1 4349/4885CYP3A4 4826/4885 |
| US-20030229068-A1 | 2-oxo-1,3,4-trihydroquinazolinyl derivatives and methods of use | CASP3, BAX, BAD | PTGS2 76/4885ALDH1A1 271/4885CYP3A4 104/4885 |
| US-20190054213-A1 | Antimicrobial Medical Devices | PPOX, CUTA, PPIA | PTGS2 684/4885ALDH1A1 3822/4885CYP3A4 2506/4885 |
| US-10806829-B2 | Antimicrobial medical devices | PPOX, CUTA, PPIA | PTGS2 684/4885ALDH1A1 3822/4885CYP3A4 2506/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.